Host: Mark Socinski, MD
Guest: Patrick Forde, M.B.B.Ch.
The optimal management of non-small cell lung cancer (NSCLC) has fundamentally changed. Targeted agents, mono and combination immunotherapy, and immunochemotherapy options continue to emerge. You also need to factor in new and investigational neoadjuvant and adjuvant regimens. So how do you determine which patients will benefit most within this new landscape of options? Join Drs. Mark Socinski and Patrick Forde as they address these questions and provide a measure of order in the chaos.
Podchaser is the ultimate destination for podcast data, search, and discovery. Learn More